Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis

Allergy and Asthma Proceedings

Volumn 32, Issue 2, 2011, Pages 151-158

  Lieberman, Phil ^a   Meltzer, Eli O ^b   LaForce, Craig F ^c   Darter, Amy L ^d   Tort, Maria J ^e  

^a Allergy and Asthma Care   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c North Carolina Clinical Research   (United States)

^d Oklahoma Allergy and Asthma Clinic   (United States)

^e ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; OLOPATADINE;

ADULT; ANKLE FRACTURE; ANKLE SPRAIN; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEMORRHOID; HUMAN; INFLUENZA A (H1N1); LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; NOSE DISEASE; NOSE IRRITATION; NOSE PAIN; NOSE REDNESS; PARALLEL DESIGN; PARANASAL SINUS DISEASE; PATIENT GLOBAL ASSESSMENT SCORE; PATIENT SATISFACTION; POSTNASAL DRIP; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHOID; RECTUML HEMORRHOID; RHINORRHEA; SINUS INFECTION; SNEEZING; SORE THROAT; TACHYCARDIA; TASTE DISORDER; TIBIA FRACTURE; TONSIL DISEASE; TONSIL INFECTION; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION; VASOMOTOR RHINITIS; VOMITING;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTI-ALLERGIC AGENTS; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL SPRAYS; PHTHALAZINES; RHINITIS, VASOMOTOR; TASTE; TREATMENT OUTCOME;

EID: 79953230847     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3439     Document Type: Article

References (25)

1. Kaliner MA. A novel and effective approach to treating rhinitis with nasal antihistamines. Ann Allergy Asthma Immunol 99: 383-390, 2007.
2. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an American survey. Allergy Asthma Proc 29:600-608, 2008.
3. Kaliner MA. The treatment of vasomotor nonallergic rhinitis. Clin Allergy Immunol 19:351-362, 2007.
4. Banov CH, and Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 86:28-35, 2001. (Pubitemid 32104567)
5. Quillen DM, and Feller DB. Diagnosing rhinitis: Allergic vs. nonallergic. Am Fam Physician 73:1583-1590, 2006. (Pubitemid 43807058)
6. Alcon Laboratories, Inc. Patanase package insert. Fort Worth, TX; 2010.
7. MedPointe Pharmaceuticals, MedPointe Healthcare, Inc. Astelin package insert. Somerset, NJ; 2007.
8. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 28:716-723, 2007.
9. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95: 600-606, 2005. (Pubitemid 43010489)
10. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
11. Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 137:918-924, 2007. (Pubitemid 350117069)
12. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 95:474-479, 2005. (Pubitemid 41688510)
13. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 103:373-380, 2009.
14. Shah SR, Nayak A, Ratner P, et al. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: A phase III, multicenter, randomized, double-blind, active-and placebo-controlled study in adolescents and adults. Clin Ther 31:99-107, 2009.
15. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12, 2004.
16. Lambiase A, Micera A, and Bonini S. Multiple action agents and the eye: Do they really stabilize mast cells? Curr Opin Allergy Clin Immunol 9:454-465, 2009.
17. Rosenwasser LJ, O'Brien T, and Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: A review of pre-clinical and clinical research. Curr Med Res Opin 21:1377-1387, 2005. (Pubitemid 41368569)
18. Kaliner MA, Oppenheimer J, and Farrar JR. Comprehensive review of olopatadine: The molecule and its clinical entities. Allergy Asthma Proc 31:112-119, 2010.
19. Bielory L, Lien KW, and Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65:215-228, 2005. (Pubitemid 40139383)
20. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 88:379-397, 2002. (Pubitemid 34516564)
21. Ciprandi G. Treatment of nonallergic perennial rhinitis. Allergy 59(suppl 76):16-22, 2004.
22. Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc 29:659-668, 2008.
23. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 131: 225-231, 2004. (Pubitemid 39208700)
24. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 62:1071-1077, 2007. (Pubitemid 47220982)
25. Waddell AN, Patel SK, Toma AG, et al. Intranasal steroid sprays in the treatment of rhinitis: Is one better than another? J Laryngol Otol 117:843-845, 2003.